Richard J. Benjamin net worth and biography

Richard Benjamin Biography and Net Worth

Chief Medical Officer of Cerus

Dr. Benjamin was appointed as our Chief Medical Officer (CMO) in July 2015. Previously, he served as CMO for the American Red Cross where he oversaw donor and patient safety issues for 40% of the US blood supply. Prior to Red Cross, he served as Medical Director at the Adult Transfusion Service at the Joint Program in Transfusion Medicine at Harvard University. Dr. Benjamin served as a Board Member and Regional Director for North America for the International Society of Blood Transfusion (ISBT) and is an active member of the Association for the Advancement of Blood & Biotherapies (AABB). He has also served on the DHHS Secretary’s Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) in the U.S. Dr. Benjamin is an Adjunct Professor of Pathology at Georgetown University and author of 130 peer-reviewed publications. He received his M.D. from the University of Cape Town and his Ph.D. from Cambridge University, England in Immunology, and he completed post-doctoral research at Stanford University, CA.

What is Richard J. Benjamin's net worth?: The estimated net worth of Richard J. Benjamin is at least $1.42 million as of March 12th, 2026. Dr. Benjamin owns 777,361 shares of Cerus stock worth more than $1,422,571 as of March 27th. This net worth approximation does not reflect any other assets that Dr. Benjamin may own. Learn More about Richard J. Benjamin's net worth.
How do I contact Richard J. Benjamin?: The corporate mailing address for Dr. Benjamin and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Richard J. Benjamin's contact information.
Has Richard J. Benjamin been buying or selling shares of Cerus?: Over the course of the past ninety days, Richard J. Benjamin has sold $419,741.61 of Cerus stock. Most recently, Richard J. Benjamin sold 101,740 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.66, for a transaction totalling $168,888.40. Following the completion of the sale, the insider now directly owns 777,361 shares of the company's stock, valued at $1,290,419.26. Learn More on Richard J. Benjamin's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Richard Benjamin (Chief Medical Officer), Eric Bjerkholt (Director), Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Jensen (Insider), Ann Lucena (Director), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), Hua Shan (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 1,194,282 shares worth more than $2,106,289.99. The most recent insider tranaction occured on March, 12th when COO Vivek K Jayaraman sold 165,200 shares worth more than $274,232.00. Insiders at Cerus own 5.6% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/12/2026.

Richard J. Benjamin Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2026	Sell	101,740	$1.66	$168,888.40	777,361
3/9/2026	Sell	40,426	$1.88	$76,000.88	879,101
3/6/2026	Sell	24,235	$2.01	$48,712.35	919,527
3/5/2026	Sell	61,233	$2.06	$126,139.98	943,762
3/13/2025	Sell	18,949	$1.45	$27,476.05	715,850
3/7/2025	Sell	26,139	$1.50	$39,208.50	734,799
3/3/2025	Sell	51,254	$1.58	$80,981.32	400,665
8/2/2024	Sell	21,605	$2.50	$54,012.50	438,007
3/8/2024	Sell	29,378	$2.40	$70,507.20	478,061
8/9/2022	Sell	10,000	$5.12	$51,200.00	172,665
8/24/2020	Sell	100,000	$7.90	$790,000.00	141,763
7/7/2020	Sell	154,583	$7.20	$1,112,997.60	141,763
8/7/2019	Sell	16,444	$5.01	$82,384.44
3/13/2019	Sell	9,890	$5.96	$58,944.40	3,000
8/14/2018	Sell	35,416	$7.20	$254,995.20	35,416
5/11/2018	Sell	8,631	$6.69	$57,741.39
3/14/2017	Sell	1,189	$4.15	$4,934.35	3,000

Richard J. Benjamin Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $1.83

$1.80

$1.91

50 Day Range

MA: $2.20

$1.69

$2.62

2 Week Range

Now: $1.83

$1.12

$2.96

Volume

870,333 shs

Average Volume

2,443,256 shs

Market Capitalization

$351.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51